The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Pregabalin for Treatment of Generalized Anxiety Disorder: A 4-Week, Multicenter, Double-blind, Placebo-Controlled Trial of Pregabalin and Alprazolam
Abstract
BACKGROUND: Pregabalin inhibits release of excess excitatory neurotransmitters, presumably by binding to the alpha2-delta subunit protein of widely distributed voltage-dependent calcium channels in the brain and spinal cord. OBJECTIVE: To assess the anxiolytic efficacy of pregabalin in patients with generalized anxiety disorder. DESIGN: Double-blind, placebo-controlled, active-comparator trial. Patients were randomized to 4 weeks of treatment with pregabalin, 300 mg/d (n = 91), 450 mg/d (n = 90), or 600 mg/d (n = 89); alprazolam, 1.5 mg/d (n = 93); or placebo (n = 91). SETTING: Psychiatry research and clinic settings. PATIENTS: Outpatients meeting the DSM-IV criteria for generalized anxiety disorder, with a baseline Hamilton Anxiety Rating Scale (HAM-A) total score of 20 or greater. MAIN OUTCOME MEASURES: Change from baseline to end point in total HAM-A score in the pregabalin and alprazolam groups compared with the placebo group. The end point response criterion was 50% or greater reduction in the HAM-A total score. RESULTS: Pregabalin and alprazolam produced a significantly greater reduction in mean +/- SE HAM-A total score at last-observation-carried-forward end point compared with placebo (-8.4 +/- 0.8): pregabalin, 300 mg (-12.2 +/- 0.8, P<.001), 450 mg (-11.0 +/- 0.8, P = .02), and 600 mg (-11.8 +/- 0.8, P = .002), and alprazolam (-10.9 +/- 0.8, P = .02). By week 1 and at last-observation-carried-forward end point, the 3 pregabalin groups and the alprazolam group had significantly (P<.01) improved HAM-A psychic anxiety symptoms compared with the placebo group. Compared with the placebo group, HAM-A somatic anxiety symptoms were also significantly (P<.02) improved by the 300- and 600-mg pregabalin groups, but not by the 450-mg pregabalin (week 1, P = .06; week 4, P = .32) and the alprazolam groups (week 1, P = .21; week 4, P = .15). Of the 5 treatment groups, the 300-mg pregabalin group was the only medication group that differed statistically in global improvement at treatment end point not only from the placebo group but also from the alprazolam group. CONCLUSION: Pregabalin was significantly more efficacious than placebo for the treatment of psychic and somatic symptoms of generalized anxiety disorder and was well tolerated by most study patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Applied Linear Statistical Models
Ziegel, E. R., Neter, J., Wasserman, W., & Kutner, M. (1992) · Technometrics · doi:10.2307/1269588 · Cited by 9,907
(1976) · Medical Entomology and Zoology · Cited by 8,899
Kupper, L. L., Hosmer, D. W., & Lemeshow, S. (1990) · Journal of the American Statistical Association · doi:10.2307/2290035 · Cited by 7,599
Applied Linear Statistical Models
(1997) · Technometrics · doi:10.1080/00401706.1997.10485141 · Cited by 7,185
Applied Linear Statistical Models.
Lorenz, F., Neter, J., Wasserman, W., & Kutner, M. H. (1986) · Journal of the American Statistical Association · doi:10.2307/2289108 · Cited by 5,565
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Categorical Data Analysis Using the SAS System
(1996) · Technometrics · doi:10.1080/00401706.1996.10484575 · Cited by 1,869
Ostwald, P. F. (1960) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1960.14.4.817 · Cited by 1,357
Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial
Dworkin, R. H., Corbin, A. E., Young, J. P., Sharma, U., LaMoreaux, L., Bockbrader, H., Garofalo, E. A., & Poole, R. M. (2003) · Neurology · doi:10.1212/01.wnl.0000055433.55136.55 · Cited by 768
Rosenstock, J., Tuchman, M., LaMoreaux, L., & Sharma, U. (2004) · Pain · doi:10.1016/j.pain.2004.05.001 · Cited by 725
Ormel, E. A. (1995) · PsycEXTRA Dataset · doi:10.1037/e536912011-072 · Cited by 706
Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial
Lesser, H., Sharma, U., LaMoreaux, L., & Poole, R. M. (2004) · Neurology · doi:10.1212/01.wnl.0000145767.36287.a1 · Cited by 570
Sabatowski, R., Gálvez, R., Cherry, D. A., Jacquot, F., Vincent, E., Maisonobe, P., & Versavel, M. (2004) · Pain · doi:10.1016/j.pain.2004.01.001 · Cited by 527
(2002) · PubMed · Cited by 518
Kessler, R. C., DuPont, R. L., Berglund, P., & Wittchen, H.-U. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.1915 · Cited by 486
Categorical Data Analysis Using the SAS System
Ziegel, E. R., Stokes, M., Davis, C., & Koch, G. (1996) · Technometrics · doi:10.2307/1271334 · Cited by 389
RASKIN, A., SCHULTERBRANDT, J., REATIG, N., & McKEON, J. J. (1969) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196901000-00010 · Cited by 373
The epidemiology of generalized anxiety disorder
Kessler, R. C., Keller, M. B., & Wittchen, H.-U. (2001) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70204-5 · Cited by 337
Fehrenbacher, J. C., Taylor, C. P., & Vasko, M. R. (2003) · Pain · doi:10.1016/s0304-3959(03)00173-8 · Cited by 336
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Self-citationCarter, R. M., Wittchen, H.-U., Pfister, H., & Kessler, R. C. (2001) · Depression and Anxiety · doi:10.1002/da.1020 · Cited by 331
Pregabalin in Generalized Anxiety Disorder: A Placebo-Controlled Trial
Pande, A. C., Crockatt, J. G., Feltner, D. E., Janney, C. A., Smith, W. T., Weisler, R., Londborg, P. D., Bielski, R. J., Zimbroff, D. L., Davidson, J. R. T., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.3.533 · Cited by 314
Self-citationDavidson, J. R. T., DuPont, R. L., Hedges, D., & Haskins, J. T. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0805 · Cited by 303
Wittchen, H.-U., Carter, R. M., Pfister, H., Montgomery, S. A., & Kessler, R. C. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015060-00002 · Cited by 299
Gelenberg, A. J., Lydiard, R. B., Rudolph, R. L., Aguiar, L., Haskins, J. T., & Salinas, E. (2000) · JAMA · doi:10.1001/jama.283.23.3082 · Cited by 296
Self-citationFeltner, D. E., Crockatt, J. G., Dubovsky, S. J., Cohn, C. K., Shrivastava, R. K., Targum, S. D., Liu-Dumaw, M., Carter, C. M., & Pande, A. C. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084032.22282.ff · Cited by 260
Self-citationPharmacokinetics of Pregabalin in Subjects with Various Degrees of Renal Function
Randinitis, E. J., Posvar, E. L., Alvey, C. W., Sedman, A. J., Cook, J. A., & Bockbrader, H. N. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003251119 · Cited by 257
Schonfeld, W. H., Verboncoeur, C. J., Fifer, S. K., Lipschutz, R. C., Lubeck, D. P., & Buesching, D. P. (1997) · Journal of Affective Disorders · doi:10.1016/s0165-0327(96)01416-4 · Cited by 247
Pollack, M. H., Zaninelli, R., Goddard, A., McCafferty, J. P., Bellew, K. M., Burnham, D. B., & Iyengar, M. K. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0508 · Cited by 246
Self-citationDose-response trial of pregabalin adjunctive therapy in patients with partial seizures
French, J. A., Kugler, A. R., Robbins, J. L., Knapp, L. E., & Garofalo, E. A. (2003) · Neurology · doi:10.1212/01.wnl.0000068024.20285.65 · Cited by 239
Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin
Dooley, D. J., Mieske, C. A., & Borosky, S. A. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00769-2 · Cited by 226
Dooley, D. J., Donovan, C. M., & Pugsley, T. A. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39009-3 · Cited by 217
Structure−Activity Relationships of Pregabalin and Analogues That Target the α2-δ Protein
Belliotti, T. R., Capiris, T., Ekhato, I. V., Kinsora, J. J., Field, M. J., Heffner, T. G., Meltzer, L. T., Schwarz, J. B., Taylor, C. P., Thorpe, A. J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049762l · Cited by 212
Endicott Work Productivity Scale (EWPS): a new measure to assess treatment effects.
Endicott, J., & Nee, J. (1997) · PubMed · Cited by 199
Paroxetine Treatment of Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Study
Rickels, K., Zaninelli, R., McCafferty, J., Bellew, K., Iyengar, M., & Sheehan, D. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.749 · Cited by 198
Self-citationRebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.7.848 · Cited by 176
Khan, A., Khan, S. R., Walens, G., Kolts, R., & Giller, E. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300059 · Cited by 158
Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity
Field, M. J., Oles, R. J., & Singh, L. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703794 · Cited by 129
Stahl, S. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0901 · Cited by 88
Outpatient treatment of neurotic depression: medication and group psychotherapy.
Lipman, R. S., & Covi, L. (1976) · PubMed · Cited by 74
Pregabalin Relieves Symptoms of Painful Diabetic Neuropathy: A Randomized Controlled Trial
Verma, A. (2006) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(08)70260-6 · Cited by 57
A controlled clinical trial of alprazolam for the treatment of anxiety
Rickels, K., Csanalosi, I., Greisman, P., Cohen, D., Werblowsky, J. H., Ross, H. A., & Harris, H. (1983) · American Journal of Psychiatry · doi:10.1176/ajp.140.1.82 · Cited by 56
Self-citationClorazepate and lorazepam: clinical improvement and rebound anxiety
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.3.312 · Cited by 50
Self-citationMeoni, P., Salinas, E. O., Brault, Y., & Hackett, D. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1109 · Cited by 39
Cited by
Pharmacologic management of neuropathic pain: Evidence-based recommendations
Dworkin, R. H., O’Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., Kalso, E. A., Loeser, J. D., Miaskowski, C., Nurmikko, T. J., et al. (2007) · Pain · doi:10.1016/j.pain.2007.08.033 · Cited by 2,126
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Benzodiazepines: Alprazolam [589-593], bromazepam”
InfluentialBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Tiippana, E. M., Hamunen, K., Kontinen, V. K., & Kalso, E. (2007) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000261517.27532.80 · Cited by 532
Depression, anxiety and acute pain: links and management challenges
Michaelides, A., & Zis, P. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1663705 · Cited by 428
Metadata
- Authors
- Rickels, K., Pollack, M. H., Feltner, D. E., Lydiard, R. B., Zimbroff, D. L., Bielski, R. J., Tobias, K., Brock, J. D., Zornberg, G. L., & Pande, A. C.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2005-09-01
- Volume
- 62
- Issue
- 9
- Pages
- 1022
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2107373225
- Cited by
- 280
- References
- 48
- FWCI
- 31.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.